Our Services
Medical Information
Helpful Resources
Published on: 9/16/2026
Zetia (ezetimibe) used alone typically lowers LDL cholesterol by about 15% to 20%, which may be sufficient for mildly elevated levels or for people who cannot tolerate statins, but it is generally less potent than statin therapy, which can reduce LDL by 30% to 50% or more. Whether monotherapy gets you to goal depends on your starting LDL number, your cardiovascular risk category, family history, and how far you need to drop, so there are several important factors to consider before assuming a statin is unnecessary. See below to understand more about target ranges, combination therapy options, and when adding or switching medications is recommended.
Because cholesterol goals are highly individual and symptoms of high cholesterol are often silent until a serious event occurs, understanding your personal risk picture matters more than a single average percentage. Take a free, instant, online symptom check to clarify what your body may be signaling and get guidance on the right next steps to discuss with a clinician.
Last reviewed for medical accuracy: 09/15/2025
Managing high cholesterol is a common concern. Zetia (active ingredient: ezetimibe) works differently from statins and can reduce LDL (“bad”) cholesterol on its own. Whether it’s enough for you depends on your individual health profile and risk factors. Below, we explain how Zetia works, how effective it is alone, and when you might still need a statin or other therapies.
Cholesterol travels through your bloodstream in particles called lipoproteins. Two key types:
Reducing LDL is a main goal of therapy:
Zetia targets cholesterol absorption in your small intestine:
Key points:
When taken alone, Zetia generally lowers LDL by about 15–20%:
By comparison, moderate-intensity statins often reduce LDL by 30–50%, and high-intensity statins by up to 60%. That means:
Statins and Zetia both lower LDL but via separate pathways:
| Feature | Zetia (ezetimibe) | Statins (e.g., atorvastatin) |
|---|---|---|
| Mechanism | Blocks intestinal absorption | Inhibits HMG-CoA reductase in liver |
| LDL reduction | ~15–20% | ~30–60% depending on potency |
| Primary use | Mild-to-moderate LDL reduction | First-line for high LDL and high risk |
| Common side effects | Diarrhea, back pain, headache | Muscle aches, liver enzyme elevations |
Because of this complementary action, many guidelines recommend adding Zetia to a statin when LDL goals aren’t met or when patients can’t tolerate high-dose statins.
Zetia monotherapy is often chosen for:
Before relying on Zetia alone, discuss:
Zetia is generally well tolerated. Common side effects include:
Rare but serious risks:
Key safety tips:
If Zetia alone doesn’t achieve your targets or you’re high-risk, consider:
Your doctor will tailor therapy based on:
No medication replaces a heart-healthy lifestyle. Key steps you can take:
Even modest improvements in diet and activity can enhance Zetia’s effects and reduce overall risk.
If you’re considering Zetia or already taking it, you might start with a:
Always talk with your doctor before starting, stopping or combining cholesterol medicines. For any serious or life-threatening symptoms—such as chest pain, severe muscle weakness or sudden shortness of breath—seek immediate medical attention.
Your health is unique. Work closely with your healthcare provider to find the safest, most effective strategy to lower your cholesterol and protect your heart.
(References)
* Bays H. Ezetimibe. Expert Opin Investig Drugs. 2002 Nov;11(11):1587-604. doi: 10.1517/13543784.11.11.1587. PMID: 12437505.
* Araújo RG, Casella Filho A, Chagas AC. [Ezetimibe--pharmacokinetics and therapeutics]. Arq Bras Cardiol. 2005 Oct;85 Suppl 5:20-4. doi: 10.1590/s0066-782x2005002400006. Epub 2006 Jan 2. PMID: 16400393.
* Yeste D, Chacón P, Clemente M, Albisu MA, Gussinyé M, Carrascosa A. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab. 2009 Jun;22(6):487-92. doi: 10.1515/jpem.2009.22.6.487. PMID: 19694195.
* Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12. PMID: 29910030.
* Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10. PMID: 30423391.
* Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003. Epub 2018 Nov 10. PMID: 30423393.
* Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29. PMID: 31357887; PMCID: PMC7153222.
* Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis. 2021 Mar;320:122-128. doi: 10.1016/j.atherosclerosis.2020.12.023. Epub 2020 Dec 31. PMID: 33514449.
* Sinning D, Landmesser U. [Hypercholesterolemia and cardiovascular risk]. Dtsch Med Wochenschr. 2023 Aug;148(16):1025-1032. doi: 10.1055/a-1932-6448. Epub 2023 Aug 4. PMID: 37541292.
* Ji X, Xia J, Zhang H, Ren C, Ma G, Fu S, Zhang J, Chen Y, Han X, Zhang J, Fang Z, Yang B, Yang B, Huang W, Yin G, Qi H, Gong H, Wang D, Hao L, Zhao X, Pei Z, Wang P, Li X, Lin L, Li D, Li Z, Zhang L, Yin B, Cheng Y, You Z, Sheng J, Wu J, Chen L, Fan Z, Zhao W, Zhao S. Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial. Lipids Health Dis. 2025 Jul 22;24(1):249. doi: 10.1186/s12944-025-02670-y. Epub 2025 Jul 22. PMID: 40696391; PMCID: PMC12281852.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.